Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:MBAI NASDAQ:PETV NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.36-0.4%$0.43$0.35▼$1.22$22.62M1.3989,066 shs37,724 shsMBAICheck-Cap$1.10-6.0%$1.36$0.59▼$3.92$8.02M0.6565,351 shs15,582 shsPETVPetVivo$0.72+2.9%$0.79$0.60▼$1.69$27.07M1.2310,829 shs9,248 shsPSTVPlus Therapeutics$3.83+1.3%$4.82$2.90▼$23.42$26.37M1.4149,022 shs61,371 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-0.39%0.00%-22.91%-42.69%-64.71%MBAICheck-Cap-5.98%+10.00%-14.73%-28.10%+109,999,900.00%PETVPetVivo+7.46%-6.31%-13.24%-9.89%-12.94%PSTVPlus Therapeutics+1.32%+2.41%-3.28%-41.97%-68.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.36-0.4%$0.43$0.35▼$1.22$22.62M1.3989,066 shs37,724 shsMBAICheck-Cap$1.10-6.0%$1.36$0.59▼$3.92$8.02M0.6565,351 shs15,582 shsPETVPetVivo$0.72+2.9%$0.79$0.60▼$1.69$27.07M1.2310,829 shs9,248 shsPSTVPlus Therapeutics$3.83+1.3%$4.82$2.90▼$23.42$26.37M1.4149,022 shs61,371 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-0.39%0.00%-22.91%-42.69%-64.71%MBAICheck-Cap-5.98%+10.00%-14.73%-28.10%+109,999,900.00%PETVPetVivo+7.46%-6.31%-13.24%-9.89%-12.94%PSTVPlus Therapeutics+1.32%+2.41%-3.28%-41.97%-68.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,393.06% UpsideMBAICheck-Cap 1.00SellN/AN/APETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 2.43Hold$56.401,372.58% UpsideCurrent Analyst Ratings BreakdownLatest MBAI, PSTV, PETV, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026MBAICheck-Cap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/6/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/8/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.20M0.61N/AN/A$0.09 per share4.00MBAICheck-CapN/AN/A$0.57 per share1.94$0.47 per shareN/APETVPetVivo$1.05M25.88N/AN/A($0.03) per share-24.00PSTVPlus Therapeutics$5.21M5.06N/AN/A$0.72 per share5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/A12.00N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)MBAICheck-Cap$4.14M-$2.01N/AN/AN/AN/AN/AN/AN/APETVPetVivo-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%8/13/2026 (Estimated)PSTVPlus Therapeutics-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)Latest MBAI, PSTV, PETV, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026N/APETVPetVivo-$0.08N/AN/AN/A$0.01 millionN/A8/13/2026Q2 2026PSTVPlus Therapeutics-$0.88N/AN/AN/A$1.11 millionN/A8/6/2026Q2 2026CTSOCytosorbents-$0.05N/AN/AN/A$9.39 millionN/A5/15/2026Q1 2026PSTVPlus Therapeutics-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AMBAICheck-CapN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81MBAICheck-CapN/A0.050.05PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A2.272.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%MBAICheck-Cap1.07%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.80%MBAICheck-Cap0.48%PETVPetVivo10.84%PSTVPlus Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.84 million57.94 millionOptionableMBAICheck-Cap807.29 million7.25 millionN/APETVPetVivo2037.59 million19.06 millionNot OptionablePSTVPlus Therapeutics206.88 million6.71 millionNot OptionableMBAI, PSTV, PETV, and CTSO HeadlinesRecent News About These CompaniesPlus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS CancerJuly 21, 2026 | finanznachrichten.dePlus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerJuly 21, 2026 | globenewswire.comPlus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay PlatformJuly 16, 2026 | globenewswire.comPlus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringJuly 14, 2026 | globenewswire.comPlus Therapeutics Inc.July 2, 2026 | barrons.comPlus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)June 30, 2026 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy TranscriptJune 30, 2026 | seekingalpha.comPlus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial ProgressJune 30, 2026 | quiverquant.comQPlus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingJune 30, 2026 | globenewswire.comPlus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration AssayJune 25, 2026 | quiverquant.comQPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerJune 25, 2026 | globenewswire.comPlus Therapeutics to Provide Business Update Call on June 30, 2026June 23, 2026 | globenewswire.comPlus Therapeutics Launches New At-The-Market Equity ProgramJune 5, 2026 | tipranks.comPlus Therapeutics gains CAP accreditation for CNSide CSF assay platformJune 4, 2026 | proactiveinvestors.comCNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical LaboratoryJune 4, 2026 | quiverquant.comQPlus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical LaboratoryJune 4, 2026 | globenewswire.comPlus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual MeetingMay 26, 2026 | quiverquant.comQPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal MetastasesMay 26, 2026 | globenewswire.comPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyMay 19, 2026 | globenewswire.comPlus Therapeutics Stockholders Back Directors and Incentive PlanMay 15, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBAI, PSTV, PETV, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$0.36 0.00 (-0.39%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.38 +0.02 (+5.56%) As of 07/24/2026 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Check-Cap NASDAQ:MBAI$1.10 -0.07 (-5.98%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.10 0.00 (0.00%) As of 07/24/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.PetVivo NASDAQ:PETV$0.72 +0.02 (+2.86%) As of 07/24/2026 03:08 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$3.83 +0.05 (+1.32%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.84 +0.01 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
